Bayer AG Stock
€27.61
Your prediction
Bayer AG Stock
Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Pros and Cons of Bayer AG in the next few years
Pros
Cons
Performance of Bayer AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG | 0.160% | -4.570% | -0.827% | -1.218% | 42.750% | -47.143% | -51.767% |
| Merck KGaA | -1.060% | -0.046% | -2.703% | -35.038% | -22.386% | -35.116% | -14.692% |
| Elanco Animal Health Inc. | 4.120% | 1.338% | 6.953% | 24.135% | 40.388% | 10.016% | -27.625% |
| Johnson & Johnson | 0.420% | -2.814% | -2.171% | -1.216% | 6.270% | -11.656% | 17.432% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Bayer, with its US ticker symbol BAYZF, is a prominent player in the pharmaceuticals industry, boasting a rich history and a diverse portfolio. A deep dive into Bayer's financials reveals a complex picture—while there are some strengths and opportunities for growth, several areas raise concerns.
When analyzing Bayer's financials, several key aspects come into play, revealing both positives and negatives that deserve attention. The company's total assets stood at approximately €123.34 billion in 2023, slightly up from €124.88 billion in 2022. A noticeable highlight is Bayer’s gross profit, which peaked at around €27.8 billion in 2023, reflecting robust revenue generation capabilities even amidst some operational challenges.
*Pros: *
Comments
News
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic